Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2022-07-01
|
| Serija: | Microbial Cell Factories |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12934-022-01873-7 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|